Anula Jayasuriya - 01 Jul 2024 Form 4 Insider Report for Lineage Cell Therapeutics, Inc. (LCTX)

Role
Director
Signature
/s/ Alexandra Hernandez, as Attorney-in-Fact
Issuer symbol
LCTX
Transactions as of
01 Jul 2024
Transactions value $
$0
Form type
4
Filing time
03 Jul 2024, 17:00:05 UTC
Previous filing
02 Jan 2024
Next filing
10 Oct 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LCTX Stock Option (Right to Buy) Award $0 +75,000 $0 75,000 01 Jul 2024 Common Shares 75,000 $0.9541 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Will vest and become exercisable on July 1, 2025, subject to the reporting person's continuous service with the issuer.